In biology, regeneration is the process of renewal, restoration, and growth that make cells and organisms resilient to natural variations or events that cause inflammation or damage. The homeostatic environment is essentially governed at the molecular level by appropriate gene regulation that activates regenerative processes as required. However, often the progression of cell/tissue regeneration can be incomplete leading to an altered physiological state.
In many diseases, development and/or progression could potentially be therapeutically addressed by either ameliorating the altered regenerative processes or through boosting the body’s natural levels to overcome the altered state. Coupled with the new translational approach to regenerative medicine, is an industry researching the potential benefits of using stem cells therapeutically as well as for screening purposes. Aquila can incorporate the use of stem cells into a number of existing protocols as well as developing new methods specific to your research.
Aquila has strong academic links and expertise in many areas of regeneration, with some examples listed below. It is our ambition to increase our coverage in this area by introducing novel models and to be the first port of call for companies interested in promoting regenerative processes. Please contact us if you have a specific project of interest.
Regeneration in Multiple Sclerosis
Aquila has a suite of assays particularly relevant to investigation of test compounds that may have potential benefits in the remyelination process:
Regeneration in Neuropathic Pain/Spinal Cord Injury
Microglia have been shown to play a key role in mediating the restorative processes linked to spinal cord injury and neuropathic pain. Within activated microglia, compound inhibition of the M1 pro-inflammatory phenotype or a switch towards the anti-inflammatory M2 phenotype has the potential to significantly improve clinical outcome.
Regeneration in Liver Fibrosis
Liver fibrosis is the physiological response characterized by excessive deposition of extracellular matrix (ECM) proteins in the form of a scar, as an attempt to limit tissue damage in chronic liver injury. Much of the therapeutic focus is on how to ‘switch-off’ this scarring mechanism, primarily led through the control of hepatic stellate cells. Aquila is developing a range of assays to determine potential therapeutic benefit of test compounds designed for the treatment of liver fibrosis as well as assessment of toxicity using:
The work that we asked Aquila BioMedical to perform was an in-vitro experiment on neural cells. It required not simply a diligent attitude in delivering the results in an agreed period, but also efficient communication skills since there was a language barrier.
Aquila BioMedical satisfied us about all of them. More than frequent conferences and e-mails between two parties also helped in elaborating a good work plan which led to a good start of the work. Timely and frequent communication helped us in clearly understanding the progress of the work and solving difficulties in a timely manner. By doing so, the results of the work were delivered to us on schedule with higher quality than we expected. Their cost performance, another very important point was also satisfactory to us.
– A Japanese pharmaceutical company